David R. Nelson, MD, director of the University of Florida Clinical and Translational Science Institute, and patient partner Summer Wadsworth are embarking on a PCORI-funded study to compare the effectiveness of the two most widely used drugs to treat hepatitis C: Harvoni and Zepatier. This study emphasizes inclusion of people from groups that have been underrepresented in research on the infection, such as those who have substance use disorders, multiple medical conditions, minorities, and mental illness. Severity of the disease and changes in the quality of patients’ daily lives during treatment will be monitored for the following three years.